Category Archives: 3922 – lorlatinib by Pfizer

Survey of ALK inhibitors effects on brain mets

Posted on November 11, 2015 by admin

This survey summarizes the results of other research to describe the current level of knowledge about how effective different ALK inhibitors are at treating brain mets. Inhibitors that are discussed include crizotinib, ceritinib, alectinib, AP26113 (brigatinib) and PF-06463922 (lorlatinib). http://www.thecco.net/article/view/6520/7543

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

06463922 phase 2 trial has started

Posted on October 22, 2015 by admin

A phase 2 trial for 06463922 – lorlatinib by Pfizer has started. To find out more details go to clinicaltrials.gov.

Posted in 3922 - lorlatinib by Pfizer, Lung cancer, Potential Treatments | Leave a comment

PF-3922 Phase 1 trial

Posted on May 16, 2015 by admin

Abstract # 8018 is about a Phase 1 study of PF- 06463922 (3922). 22 patients were studied (18 ALK+ & 4 ROS1+). 17 had central nervous system (CNS) metastases and 19 had prior ALK inhibitor treatment (either 1 or 2). … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

ASCO links

Posted on May 14, 2015 by admin

Here are 18 ALK+ related abstract links related to the drugs listed below. On the ASCO website 77 abstracts refered to both “ALK” and “Inhibitor”.  When I get a chance I will write up a summary on some of the … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro | Leave a comment

Pfizer update

Posted on January 19, 2015 by admin

Pfizer announced that in 2015 the are going to start trials that combine imunitherapy (PDL-1 and PD-1) drugs with its two ALK inhibitor drugs. Pfizer is planning a potential pivotal study of PF-06463922 starting in 2015. By the end of … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, crizotinib - Xalkori from Pfizer, Imunotherapies | Leave a comment